Stock & Company Details
Compugen Ltd $CGEN
Price:
N/A
N/A
N/A
$201M
52 Week High:
N/A
10 Day Average Volume:
N/A
5.91
50 Day Moving Average:
N/A
52 Week Low:
N/A
30 Day Average Volume:
N/A
N/A
N/A
N/A
30 Day Change:
N/A
3 Month Change:
N/A
Health Technology
CGEN technical indicators
Latest Compugen Ltd (CGEN) indicator readings as of 2026-10-09.
CGEN's 14-day RSI is 31.0, in neutral territory. At $2.13 it is trading 6.2% below its 200-day moving average of $2.27, and below its 50-day average of $2.44. Price sits near the lower Bollinger Band ($2.12 to $2.57). ADX reads 16.2, indicating a range-bound market rather than a trend.
Overview
Compugen is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable, predictive computational discovery platforms to identify novel drug targets and develop therapeutics in the field of cancer immunotherapy. The Company's lead product candidate, COM701, a first-in-class anti-PVRIG antibody, for the treatment of solid tumors, is undergoing a Phase 1 clinical study. In addition, COM902, Compugen's antibody targeting TIGIT, is expected to enter the clinic in early 2020. The Company's therapeutic pipeline also includes early-stage immuno-oncology programs focused largely on myeloid targets. Compugen's business model is to selectively enter into collaborations for its novel targets and related drug product candidates at various stages of research and development. The Company is headquartered in Israel, with offices in South San Francisco, CA.
Finance Bot
Ask your questions
Start by typing a question below.
